PriceTargets.com logo

NASDAQ:BIVI - BioVie Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.00
  • Forecasted Upside: 60.19 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$29.34 As of 03/1/2021 11:46 AM ET
▼ -2.76 (-8.60%)
1 month | 3 months | 12 months
Get New BioVie Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIVI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIVI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$47.00
▲ +60.19% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BioVie in the last 3 months. The average price target is $47.00, with a high forecast of $47.00 and a low forecast of $47.00. The average price target represents a 60.19% upside from the last price of $29.34.
Buy
The current consensus among 1 contributing investment analysts is to buy stock in BioVie.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/15/2021B. RileyInitiated CoverageBuy$47.00High
i
Rating by M. Mamtani at B. Riley
(Data available from 3/1/2016 forward)
BioVie logo
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.
Read More

Today's Range

Now: $29.34
$28.41
$33.16

50 Day Range

MA: $35.33
$24.44
$44.81

52 Week Range

Now: $29.34
$2.20
$46.10

Volume

1,190 shs

Average Volume

97,487 shs

Market Capitalization

$408.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of BioVie?

The following Wall Street analysts have issued research reports on BioVie in the last year: B. Riley.
View the latest analyst ratings for BIVI.

What is the current price target for BioVie?

1 Wall Street analysts have set twelve-month price targets for BioVie in the last year. Their average twelve-month price target is $47.00, suggesting a possible upside of 46.4%. B. Riley has the highest price target set, predicting BIVI will reach $47.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $47.00 for BioVie in the next year.
View the latest price targets for BIVI.

What is the current consensus analyst rating for BioVie?

BioVie currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIVI will outperform the market and that investors should add to their positions of BioVie.
View the latest ratings for BIVI.

What other companies compete with BioVie?

Other companies that are similar to BioVie include Aurinia Pharmaceuticals, Pandion Therapeutics, Revance Therapeutics, Seres Therapeutics, Shattuck Labs, Arcutis Biotherapeutics, Zentalis Pharmaceuticals, Applied Molecular Transport, ImmunoGen, PMV Pharmaceuticals, Praxis Precision Medicines, Zymeworks, Frequency Therapeutics, Heron Therapeutics and Organogenesis.

How do I contact BioVie's investor relations team?

The company's listed phone number is 312 283 5793. The official website for BioVie is www.biovieinc.com.